Search

Displaying results 3001 - 3010 of 3864 in total
  1. Drug

    Diacerein

    go.drugbank.com/drugs/DB11994
    ApprovedInvestigationalWithdrawn

    Diacerein is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea . Diacerein is und...

    Mixtures: CARTIGEN NF
  2. Drug

    HMR4011

    go.drugbank.com/drugs/DB06225
    Experimental

    HMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid.

  3. Drug

    Cyclic adenosine monophosphate

    go.drugbank.com/drugs/DB02527
    Investigational

    Cyclic adenosine monophosphate (cAMP, cyclic AMP or 3'-5'-cyclic adenosine monophosphate) is a molecule that is important in many biological processes; it is derived from adenosine triphosphate (ATP).

  4. Drug

    Depulfavirine

    go.drugbank.com/drugs/DB18890
    Investigational

    Depulfavirine is under investigation in clinical trial NCT05204394 (Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2nrtis From the 1st Line Standard of Care Therapy).

    Synonyms: 2-[4-Bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide, Benzeneacetamide, N-[4-(aminosulfonyl)-2-chlorophenyl]-4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluoro-
  5. Drug

    Amlexanox

    go.drugbank.com/drugs/DB01025
    ApprovedWithdrawn

    Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. Recurrent aphthous ulcer (RAU)...

  6. Drug

    Naloxegol

    go.drugbank.com/drugs/DB09049
    ApprovedInvestigational

    Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult pati...

  7. Drug

    Nifurtimox

    go.drugbank.com/drugs/DB11820
    ApprovedInvestigational

    On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials.

  8. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    over classic hypnotic agents, including a more favorable adverse effect profile and potentially greater efficacy, and may signal the beginning of a new wave of treatment options for patients suffering from

  9. Drug

    Ambrisentan

    go.drugbank.com/drugs/DB06403
    ApprovedInvestigational

    As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.

  10. Drug

    Cobamamide

    go.drugbank.com/drugs/DB11191
    ApprovedNutraceutical

    This drug is available as a nutritional supplement to prevent vitamin B12 deficiency. Vitamin B12 is a collective term for these variously substituted corrinoids.